Buchinger Wilhelmi: what therapeutic fasting might offer in Parkinson's disease

Can fasting help people living with Parkinson's disease? The question sounds like a promise of a cure, but the fasting clinic Buchinger Wilhelmi asks it in deliberately sober terms. The occasion is an ARTE documentary and a pilot study that delivers the first clinical data. The family business, with clinics in Überlingen on Lake Constance and in Marbella, describes both and draws a clear line between hope and evidence.

A patient on camera

In the ARTE documentary "Les bienfaits du jeûne thérapeutique", Martine, who lives with Parkinson's, talks about the role fasting plays in her life. She fasts regularly, including medically supervised stays at Buchinger Wilhelmi, and describes positive changes in how she manages her symptoms. The clinic itself is careful about what follows from this: a single experience cannot establish clinical effectiveness. It is a reason to look more closely.

What the pilot study measured

Researchers from the University of Luxembourg, Charité Berlin and other European institutions followed 31 patients with Parkinson's disease. The protocol had two phases. First, participants fasted for seven days, consuming no more than 350 calories a day. This was followed by twelve months of time-restricted eating, with all meals taken within a daily window of eight hours.

The preliminary results are encouraging. The researchers observed improvements in motor symptoms, including movement difficulties, stiffness and tremor, as well as a reduction in certain non-motor symptoms. Measures of anxiety and depression improved too. What stands out is the duration: in several clinical assessments, improvements were still seen at the twelve-month follow-up.

Why the data call for caution

Buchinger Wilhelmi names the weaknesses of the study itself. It was small, it had no control group that did not fast, and the fasting period was combined with a subsequent change in diet. It is therefore not yet possible to say how much of the improvement is due to fasting itself. The work has so far appeared as a preprint, before review by other experts. Only controlled clinical trials can show whether the findings hold and which patients might benefit most.

The clinic states the limit without ambiguity. Therapeutic fasting has not been established as a treatment that slows or reverses the progression of Parkinson's disease, and it must never replace conventional medical care.

Who may fast and who may not

How seriously the clinic takes that limit shows in how it selects patients. Medically supervised fasting may be considered only for carefully selected people at an early stage of the disease, and only after a comprehensive medical assessment. As the disease progresses, some patients lose weight unintentionally, develop nutritional deficiencies or lose muscle mass and strength. In these circumstances, prolonged fasting can carry additional risks.

Before any decision, the medical team therefore reviews each patient's overall health, nutritional status, physical condition, current medication and stage of disease. Where fasting is not advisable, the clinic turns to individually tailored nutritional strategies. Protecting the patient's health always comes first.

Our view

Buchinger Wilhelmi draws on more than 100 years of clinical experience with therapeutic fasting and runs its own research department. That makes its restraint in reading the new data all the more notable. For people with Parkinson's, the message is this: the lead is interesting, but it is not a recommendation. Anyone considering fasting should first talk it through with their neurologist.